210 related articles for article (PubMed ID: 25785448)
21. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
22. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.
Bedimo R; Kang M; Tebas P; Overton ET; Hollabaugh K; McComsey G; Bhattacharya D; Evans C; Brown TT; Taiwo B
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):325-8. PubMed ID: 26499270
[TBL] [Abstract][Full Text] [Related]
23. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
24. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
25. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
26. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
27. HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
Rivero-Juarez A; López-Cortés LF; Camacho A; Torres-Cornejo A; Gordon A; Ruiz-Valderas R; Torre-Cisneros J; Pineda JA; Viciana P; Rivero A
PLoS One; 2014; 9(6):e99468. PubMed ID: 24945348
[TBL] [Abstract][Full Text] [Related]
28. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
29. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
[TBL] [Abstract][Full Text] [Related]
30. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
[TBL] [Abstract][Full Text] [Related]
31. Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection.
Serpa JA; Rueda AM; Somasunderam A; Utay NS; Lewis D; Couturier JP; Breaux KG; Rodriguez-Barradas M
Clin Infect Dis; 2017 Oct; 65(10):1638-1643. PubMed ID: 29020215
[TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
[TBL] [Abstract][Full Text] [Related]
33. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
[TBL] [Abstract][Full Text] [Related]
35. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.
Odolini S; Amadasi S; Cerini C; Giralda M; Nasta P; Castelli F
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S4. PubMed ID: 25236496
[TBL] [Abstract][Full Text] [Related]
36. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
[TBL] [Abstract][Full Text] [Related]
38. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
Jain MK; Adams-Huet B; Terekhova D; Kushner LE; Bedimo R; Li X; Holodniy M
J Viral Hepat; 2015 Jan; 22(1):25-36. PubMed ID: 24506344
[TBL] [Abstract][Full Text] [Related]
39. High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.
Nien HC; Hsu SJ; Su TH; Yang PJ; Sheu JC; Wang JT; Chow LP; Chen CL; Kao JH; Yang WS
PLoS One; 2017; 12(1):e0170028. PubMed ID: 28107471
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
Soriano V; Maida I; Núñez M; García-Samaniego J; Barreiro P; Martín-Carbonero L; González-Lahoz J
Antivir Ther; 2004 Dec; 9(6):987-92. PubMed ID: 15651757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
